This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by SUNDSFJORD, J. A. Articles by CANTIN, M. Search for Related Content PubMed PubMed Citation Articles by SUNDSFJORD, J. A. Articles by CANTIN, M.

Identification and Plasma Concentrations of the N-Terminal Fragment of Proatrial Natriuretic Factor in Man^*

J. A. SUNDSFJORD, G. THIBAULT and M. CANTIN

Clinical Research Institute of Montreal Montreal, Quebec, Canada H2W1R7

Address all correspondence and requests for reprints to: Dr. G. Thibault, Clinical Research Institute of Montreal, 110 Ouest avenue des Pins, Montreal, Quebec, Canada N2W 1R7.

A specific RIA was developed to measure plasma atrial natriuretic factor (ANF) N-terminal immunoreactivity in man. Antibodies raised in rabbits against a rat ANF N-terminal fragment [ANF-(11–37)] had 100% cross-reactivity with human ANF-(1–30) and purified plasma N-terminal ANF immunoreactivity. The ED₈₀ and ED₅₀ of standard curves prepared using [¹²⁵I]human ANF-(l–30) and human ANF-(l–30) were 31.5 ± 5.4 (±SD) and 132.5 ± 20.4 fmol/tube, respectively. The plasma ANF N-terminal peptide concentrations were assayed directly, without extraction, since dilution of plasma and addition of standard to plasma yielded parallel dose-responses in the RIA and virtually 100% recovery of ANF-(1–30) added to plasma. Purification of ANF N-terminal immunoreactivity from 1.5 L human plasma by affinity chromatography and amino acid sequencing suggested that it was closely related to ANF-(l–98), although some degraded peptides were also detected.

The mean basal plasma ANF N-terminal peptide level measured in 34 normal subjects was 420 ± 157 (±SD) pmol/L. The values were higher in plasma from patients with congestive heart failure (grades III and IV; 7,041 ± 6,136 pmol/L; n = 13) or chronic renal failure (10,079 ± 4,942 pmol/L; n = 20). In 9 patients with chronic renal failure, hemodialysis resulted in a 30% (P < 0.05) decrease in plasma ANF-(99–126) levels, from 34.7 ± 12.3 (±SD) to 23.2 + 6.1 pmol/L, but no changes in plasma ANF N-terminal peptide concentrations.

These data indicate that the N-terminal portion of pro-ANF is cosecreted with ANF-(99–126). Its higher plasma levels in the basal state and during chronic renal failure suggest a different process of elimination than that of ANF-(99–126), which may be partly mediated by the kidney.

^* This work was supported by a Group Grant from the Medical Research Council of Canada to the Multidisciplinary Research Group on Hypertension, the National Research Council, Bio-Méga, Inc., the Pfizer Co. (England), and the Canadian Heart Foundation.

Present address: University of Tromsö, Institute of Medical Biology, Tromsö, Norway.

Received July 29, 1987.

This article has been cited by other articles:

				A.I. Larsen, K. Dickstein, N.S. Ahmadi, T. Aarsland, J.T. Kvaloy, and C. Hall The effect of altering haemodynamics on the plasma concentrations of natriuretic peptides in heart failure Eur J Heart Fail, October 1, 2006; 8(6): 628 - 633. [Abstract] [Full Text] [PDF]

				M. Brueckmann, G. Huhle, S. Lang, K. K. Haase, T. Bertsch, C. Weiss, J. J. Kaden, C. Putensen, M. Borggrefe, and U. Hoffmann Prognostic Value of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Patients With Severe Sepsis Circulation, July 26, 2005; 112(4): 527 - 534. [Abstract] [Full Text] [PDF]

				M. S. Sabatine, D. A. Morrow, J. A. de Lemos, T. Omland, M. Y. Desai, M. Tanasijevic, C. Hall, C. H. McCabe, and E. Braunwald Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia J. Am. Coll. Cardiol., November 16, 2004; 44(10): 1988 - 1995. [Abstract] [Full Text] [PDF]

				M. Heringlake, C. Heide, L. Bahlmann, W. Eichler, H. Pagel, P. Schmucker, R. Wergeland, F. P. Armbruster, and S. Klaus Effects of tilting and volume loading on plasma levels and urinary excretion of relaxin, NT-pro-ANP, and NT-pro-BNP in male volunteers J Appl Physiol, July 1, 2004; 97(1): 173 - 179. [Abstract] [Full Text] [PDF]

				R. S. McKelvie, J.-L. Rouleau, M. White, R. Afzal, J. B. Young, A. P. Maggioni, P. Held, and S. Yusuf Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure Eur. Heart J., October 1, 2003; 24(19): 1727 - 1734. [Abstract] [Full Text] [PDF]

				H. Persson, K. Andreasson, T. Kahan, S. V. Eriksson, B. Tidgren, P. Hjemdahl, C. Hall, and L. Erhardt Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists Eur J Heart Fail, January 1, 2002; 4(1): 73 - 82. [Abstract] [Full Text] [PDF]

				V Tervonen, K Kokkonen, H Vierimaa, H Ruskoaho, and O Vuolteenaho Temperature has a major influence on cardiac natriuretic peptide in salmon J. Physiol., October 1, 2001; 536(1): 199 - 209. [Abstract] [Full Text] [PDF]

				J. A. Smith, D. Bruusgaard, E. Bodd, and C. Hall Relations between medical history, clinical findings and plasma N-terminal proatrial natriuretic peptide in patients in primary health care Eur J Heart Fail, June 1, 2001; 3(3): 307 - 313. [Abstract] [Full Text] [PDF]

				M. Hurlen, T. Hole, I. Seljeflot, and H. Arnesen Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction Eur J Heart Fail, March 1, 2001; 3(2): 203 - 207. [Abstract] [Full Text] [PDF]

				A. Sigurdsson, S.V. Eriksson, C. Hall, T. Kahan, and K. Swedberg Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study Eur J Heart Fail, January 1, 2001; 3(1): 69 - 78. [Abstract] [Full Text] [PDF]

				G. A Sagnella Practical implications of current natriuretic peptide research Journal of Renin-Angiotensin-Aldosterone System, December 1, 2000; 1(4): 304 - 315. [PDF]

				C. J. Pemberton, M. L. Johnson, T. G. Yandle, and E. A. Espiner Deconvolution Analysis of Cardiac Natriuretic Peptides During Acute Volume Overload Hypertension, September 1, 2000; 36(3): 355 - 359. [Abstract] [Full Text] [PDF]

				N Suskin, R.S McKelvie, R.J Burns, R Latini, D Pericak, J Probstfield, J.L Rouleau, C Sigouin, C.B Solymoss, R Tsuyuki, et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure Eur. Heart J., August 2, 2000; 21(16): 1368 - 1375. [Abstract] [PDF]

				Effects of Metoprolol CR in Patients With Ischemic and Dilated Cardiomyopathy : The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study Circulation, February 1, 2000; 101(4): 378 - 384. [Abstract] [Full Text] [PDF]

				C. J. Pemberton, T. G. Yandle, M. T. Rademaker, C. J. Charles, G. D. Aitken, and E. A. Espiner Amino-terminal proBNP in ovine plasma: evidence for enhanced secretion in response to cardiac overload Am J Physiol Heart Circ Physiol, October 1, 1998; 275(4): H1200 - H1208. [Abstract] [Full Text] [PDF]

				Y. Numata, K. Dohi, A. Furukawa, S. Kikuoka, H. Asada, T. Fukunaga, Y. Taniguchi, K. Sasakura, T. Tsuji, K. Inouye, et al. Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptidein human plasma Clin. Chem., May 1, 1998; 44(5): 1008 - 1013. [Abstract] [Full Text] [PDF]

				W. E. Hopkins and C. Hall Paradoxical Relationship Between N-Terminal Proatrial Natriuretic Peptide and Filling Pressure in Adults With Cyanotic Congenital Heart Disease Circulation, October 7, 1997; 96(7): 2215 - 2220. [Abstract] [Full Text]

				H. Leskinen, O. Vuolteenaho, M. Toth, and H. Ruskoaho Atrial Natriuretic Peptide (ANP) Inhibits Its Own Secretion via ANPA Receptors: Altered Effect in Experimental Hypertension Endocrinology, May 1, 1997; 138(5): 1893 - 1902. [Abstract] [Full Text] [PDF]

				H. Leskinen, O. Vuolteenaho, and H. Ruskoaho Combined Inhibition of Endothelin and Angiotensin II Receptors Blocks Volume Load–Induced Cardiac Hormone Release Circ. Res., January 1, 1997; 80(1): 114 - 123. [Abstract] [Full Text]

				K. Yamamoto, J. C. Burnett Jr, M. Jougasaki, R. A. Nishimura, K. R. Bailey, Y. Saito, K. Nakao, and M. M. Redfield Superiority of Brain Natriuretic Peptide as a Hormonal Marker of Ventricular Systolic and Diastolic Dysfunction and Ventricular Hypertrophy Hypertension, December 1, 1996; 28(6): 988 - 994. [Abstract] [Full Text]

				T. Omland, A. Aakvaag, V. V. S. Bonarjee, K. Caidahl, R. T. Lie, D. W. T. Nilsen, J. A. Sundsfjord, and K. Dickstein Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term Survival After Acute Myocardial Infarction : Comparison With Plasma Atrial Natriuretic Peptide and N-Terminal Proatrial Natriuretic Peptide Circulation, June 1, 1996; 93(11): 1963 - 1969. [Abstract] [Full Text]

				H. Vierimaa, M. Hirvinen, V. Tervonen, O. Arjamaa, H. Ruskoaho, and O. Vuolteenaho Pronatriuretic peptide is a sensitive marker of the endocrine function of teleost heart Am J Physiol Endocrinol Metab, April 1, 2002; 282(4): E843 - E850. [Abstract] [Full Text] [PDF]